Artrya Limited (AU:AYA) has released an update.
Artrya Limited is poised to submit their 510(k) application for FDA approval of their Salix product, following a constructive second Q-Submission meeting that confirmed the company’s regulatory strategy is on track. The Australian medical technology firm’s AI platform aims to enhance coronary artery disease diagnosis, and CEO Mathew Regan anticipates a smooth path to application submission.
For further insights into AU:AYA stock, check out TipRanks’ Stock Analysis page.
